SBMT President

SBMT Elects Jason Cormier, MD as it 19th President in order to Promote and Advance, Neuro-Technology, Innovation, Policies, Research, Development and Diversity in field of Brain Mapping and Therapeutics.

Jason Cormier

I am both humbled and honored to be elected as the 19th president of the Society of Brain Mapping and Therapeutics. It has been an extreme privilege to be part of such an elite group of scientists, in addition to the movement towards a safer world environment, especially in the face of a very challenging time in global health and mental illness. Thinking about both the immediate and long-term effects from the Global COVID-19 pandemic, the economic catastrophes led to more complicated issues not only from a medical health standpoint, it burdened several workforce’s with depression and other mental health issues. The Society of Brain Mapping and Therapeutics remained engaged from pushing global policy to publishing landmark papers, particularly the most recent and most comprehensive review of Covid-19. Additionally, the organization distributed 700 meals to the frontline workers during the pandemic and the curfew but also advocated for the California proposition 14, which is a $5.5B intended for stem cell and other medical research, including training; stem cell therapy development and delivery; research facility construction; and associated administrative expenses. $1.5 billion dedicated to research and therapy for Alzheimer’s, Parkinson’s, stroke, epilepsy, and other brain and central nervous system diseases and conditions. It will further provide for the expansion programs promoting stem cell and other medical research, therapy development and delivery, and student and physician training and fellowships.

As president of the Society of Brain Mapping and Therapeutics, my vision and goals remain furthering global policies for fast-tracking therapeutics, impacting thoughtful regulatory reform in collaboration with the FDA and encouraging a more innovative application of technologies, like infrared thermal technology, not only for prescreening of COVID19/flu patients but also for integrating it more into the clinical setting. I will also work with 20 subcommittees within the Society of Brain Mapping and Therapeutics to help transform the treatment of dementias, degenerative neurological diseases, and brain cancer with the same urgency by which we have tackled this pandemic. I understand these are ambitious goals, but I believe that the Society and its vast global network could help achieve this vision with the collaborative efforts as they continue to strengthen, the Technological advances are both urgent and necessary.

As a neurosurgeon, I have and will continue to advocate and utilize emerging technologies such as neurophotonics, nanotechnology, Artificial intelligence/machine learning, stem cell/cellular therapeutics, augmented reality, virtual reality, avatar, supercomputing, and predictive modeling in my operating room during brain surgery, which are fostered by studies, clinical trials and research consortia conducted by Dr Kateb and Society of Brain Mapping and Therapeutics subcommittees. Such technologies are now respected and embraced by Neurosurgery and Neuroscience communities. This is an all inclusive effort with Diversity of ideas, backgrounds, gender, and races in science bringing forth innovation. It will be my ongoing mission to encourage an even more diverse and cross disciplinary work at SBMT with more participation by our female and minorities colleagues so we can create a united front to address neurological disorders. These endeavors, will continue to be the transformational voice that is heard and never silenced.

My predecessor, Professor Robert Hariri, MD, PhD, and I continue a push for prioritizing cellular therapy and stem cell use for the treatment of neurological disorders. Dr. Hariri’s leadership during the pandemic years brought us a global unity and collaboration for introducing an FDA approved Celularity immunotherapy treatment for COVID19. We will continue building on this momentum by building more collaboration across institutions across the globe, which will capitalize of the society’s global reputation and popularity. I am deeply confident that together with the SBMT leadership we will foster those relationships while substantiating the bridge to the industry, other associations, non-profits, academic centers, and investment community partners. We will also make our Brain Technology and Innovation Park initiative a priority and work with the President Biden and Vice President Harris to make this vision a reality. I would also like to take this opportunity to congratulate President Joe Biden and VP Harris for their steadfast approach to the American recovery and strongly belief BTIP align with their vision for creating biotech jobs in the USA.

I am grateful for this opportunity and look forward to the challenging year ahead for achieve the society’s mission and vision.

Jason Cormier, MD
19th President of SBMT (2021-22)

History of the Society for Brain Mapping and Therapeutics (SBMT)

Over the 16 years since its founding, the SBMT has fostered dramatic advances in brain measurement and therapy by bringing about a pioneering transformation of the way in which leaders and innovators interact in advancing the science and technology of brain science. The SBMT draws its own structure from the massively parallel and reciprocal connection principle that is so tremendously effective in the human brain itself: the SBMT has a broad, dynamic focus for reciprocally connecting scientists and entrepreneurs. The advancements of our understanding the brain and nervous system support that focus by drawing on the widest possible array of inputs and sources. At remarkable annual meetings, SBMT has drawn together:

  • Space scientists from NASA and the Jet Propulsion Lab (JPL),
  • Technology champions from DARPA (the Defense Advanced Research Projects Agency) and the military branches and the Los Alamos National Laboratory,
  • The collective academic neuroscientists from hundreds of research universities around the world,
  • Major governmental agencies supporting clinical science such as the National Institutes of Health (NIH) and the Veterans Administration,
  • The President of the United States and political leaders from the US Congress that keep our nation focused on serving the people through the advancement of science,
  • Leading clinical scientists from the fields of neurosurgery, neurology, psychiatry, orthopedics, anesthesiology, and physical medicine,
  • Scientists and other leadership from the world's leading technology corporations.
  • Industry leaders (device and pharmaceutical)
  • International delegations from all continents